Gastric retained gabapentin dosage form

Details Gastric retained gabapentin dosage form Gastric retained gabapentin dosage form

2008-09-26

2010-06-08

Sheikh, Humera N (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S464000, C424S472000, C424S489000

Reexamination Certificate

active

07731989

ABSTRACT:
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3977404 (1976-08-01), Theeuwes
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4152326 (1979-05-01), Hartenstein et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4462839 (1984-07-01), McGinley et al.
patent: 4612008 (1986-09-01), Wong et al.
patent: 4894476 (1990-01-01), Butler et al.
patent: 4996058 (1991-02-01), Sinnreich et al.
patent: 5007790 (1991-04-01), Shell
patent: 5084479 (1992-01-01), Woodruff et al.
patent: 5232704 (1993-08-01), Franz et al.
patent: 5382435 (1995-01-01), Geary et al.
patent: 5582837 (1996-12-01), Shell
patent: 5872984 (1999-02-01), Berglund et al.
patent: 5906832 (1999-05-01), Jao et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 6024982 (2000-02-01), Oshlack et al.
patent: 6054482 (2000-04-01), Augart et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6162466 (2000-12-01), Licht et al.
patent: 6255526 (2001-07-01), Pesachovich et al.
patent: 6273340 (2001-08-01), Rivailler et al.
patent: 6294690 (2001-09-01), Deering et al.
patent: 6310098 (2001-10-01), Guttuso, Jr.
patent: 6333352 (2001-12-01), Derakhshan
patent: 6340475 (2002-01-01), Shell et al.
patent: 6350471 (2002-02-01), Seth
patent: 6451808 (2002-09-01), Cowles
patent: 6465012 (2002-10-01), Vilkov
patent: 6488962 (2002-12-01), Berner et al.
patent: 6488964 (2002-12-01), Bruna et al.
patent: 6635280 (2003-10-01), Shell et al.
patent: 6635281 (2003-10-01), Wong et al.
patent: 6682759 (2004-01-01), Lim et al.
patent: 6683112 (2004-01-01), Chen et al.
patent: 6723340 (2004-04-01), Gusler et al.
patent: 7438927 (2008-10-01), Berner et al.
patent: 2001/0043946 (2001-11-01), Vilkov
patent: 2002/0012679 (2002-01-01), Bruna et al.
patent: 2002/0115705 (2002-08-01), Magnus-Miller et al.
patent: 2003/0031711 (2003-02-01), Fara et al.
patent: 2003/0044466 (2003-03-01), Markey et al.
patent: 2003/0064036 (2003-04-01), Petereit et al.
patent: 2003/0091630 (2003-05-01), Louie-Helm et al.
patent: 2003/0100611 (2003-05-01), Berner et al.
patent: 2003/0104052 (2003-06-01), Berner et al.
patent: 2003/0104053 (2003-06-01), Gusler et al.
patent: 2003/0104062 (2003-06-01), Berner et al.
patent: 2003/0133985 (2003-07-01), Louie-Helm et al.
patent: 2003/0152622 (2003-08-01), Louie-Helm et al.
patent: 2004/0062802 (2004-04-01), Hermelin
patent: 2005/0064036 (2005-03-01), Berner et al.
patent: 2006/0094785 (2006-05-01), Guttoso, Jr.
patent: 2006/0159743 (2006-07-01), Berner et al.
patent: 2006/0264509 (2006-11-01), Fraser et al.
patent: 2007/0184104 (2007-08-01), Berner et al.
patent: 2220038 (1999-07-01), None
patent: 0 458 751 (1991-05-01), None
patent: 1 118 321 (2001-07-01), None
patent: WO-98/55107 (1998-12-01), None
patent: WO-99/12537 (1999-03-01), None
patent: WO-00/59477 (2000-10-01), None
patent: WO-00/76478 (2000-12-01), None
patent: WO-01/13894 (2001-03-01), None
patent: WO-01/97612 (2001-12-01), None
patent: WO-01/97782 (2001-12-01), None
patent: WO-03/002101 (2003-01-01), None
patent: WO-03/002151 (2003-01-01), None
patent: WO-03/035040 (2003-01-01), None
Sirkiä, T. et al. “Use of Hydrophilic Polymers to Control Drug Release from Press-Coated Oxybutynin Hydrochloride Tablets”,S.T.P. Pharma Sciences, 3(6):453-458 (1993).
U.S. Appl. No. 09/425,491, Shell et al.
U.S. Appl. No. 10/045,816, Bemer et al.
Andrews et al., “Gabapentin: a new agent for the management of epilepsy,” Ann. Pharmacother. 28:1188-1196 (1994).
Asconape et al., “Myclonus associated the use of gabapentin,” Epilepsia 41:479-481 (2000).
Ashton et al., “GABA-ergic drugs: exit stage left, enter stage right”,Journal of psychopharmacology, 17(2):174-178 (2003).
Backonja et al., “Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes milletus,” JAMA 280:1831-1836 (1998).
Bebin et al., “New anticonvulsant drugs: focus on flunarizine, fosphenytoin, midazolam and stiripentol,” Drugs 48:153-171 (1994).
Benedetti, “Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies,” Fund. Clin. Pharmac. 14:301-319 (2000).
Benetello et al. (1997) Oral gabapentin disposition in patients with epilepsy after a high-protein meal:Epilepsia, 38(10):1140-1142.
Ben-Menachem, “New antiepileptic drugs and non-pharmacological treatments,” Curr. Opin. Neurol. 13:165-170 (2000).
Bennett et al. (2004) “Gabapentin in the treatment of neurophathic pain”Palliative Med., 18(1):5-11.
Bennett et al. (Aug. 2000) “Future directions in the management of pain by intraspinal drug delivery”J. Pain and Symptom Management, 20(2):S44-S50.
Bernus et al., “Anticonvulsant therapy in aged patients: clinical pharmacokinetic considerations,” Drugs & Aging 10:278-289 (1997).
Beydoun, “Monotherapy trial of new antiepileptic drugs,” Epilepsia 38 (Supp. 9):S-21-S31 (1997).
Bialer, “Comparative pharmacokinetics of the newer antiepilieptic drugs,” Clin. Pharmacokinet. 24:441-452 (1993).
Blum et al., “Pharmacokinetics of gabapentin in subject with various degrees of renal function,” Clin. Pharmacol. Ther. 56:154-159 (1994).
Bourgeois, “Important pharmacokinetic properties of antiepileptic drugs,” Epilepsia 36 (Supp. 5):S1-S7 (1995).
Bourgeois, “New antiepileptic drugs,” Arch. Neurol. 55:1181-1183 (1998).
Bourgeois, “Pharmacokietic properties of current antiepileptic drugs: what improvements are needed?” Neurology 55 (Supp. 3):S11-S16 (2000).
Boyd et al., “Clinical research: effects of age and gender on single-dose pharmacokinetics of gabapentin,” Epilepsia 40:474-479 (1999).
Brown et al., “Cloning and deletion mutagenesis of the α2δ calcium channel subunit from porcine cerebral cortex,” J. Biol. Chem. 273:25458-25465 (1998).
Browne, “Long-term efficacy and toxicity of gabapentin,” Neurology 43:A307 (1993).
Chadwick et al., “Clinical administration of new antiepileptic drugs,”an overview of safety and efficacy, Epilepsia 37 (Supp 6):S17-S22 (1996).
Chadwick, “An overview of the efficacy and tolerability of new antiepileptic drugs,” Epilepsia 38 (Supp 1):S59-S62 (1997).
Chadwick, “Gabapentin,” Lancet 343:89-91 (1994).
Cramer et al., “New antiepileptic drugs: comparison of key clinical trials,” Epilepsia 40:590-600 (1999).
Curry et al., “Newer antiepileptic drugs for children: gabapentin, felbamate, topirimate and fosphenytoin,” Am. Family Physician 57:513-520 (1998).
Davis et al. “Relationship between the rate of appearance of oxyprenolol in the Systematic Circulation and the Location of an Oxyprenolol Oros 16/260 Drug Delivery System Within the Gastrointestinal Tract as Determined by Scintigraphy”,Br. J. Clin. Pharmac., 26:435-443 (1988).
Davis, S.S. et al. “Transit of pharmaceutical dosage forms through the small intestine”,Gut, 27:886-892 (1986).
Davis, S.S. et al., “The effect of density on the gastric emptying of single- and multiple-unit dosage forms”,Pharmaceutical Research, 3(4):208-213 (1986).
Devinsky et al., “New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine and vigabatrin,” J. Child Neurology 9 (Supp 1):S33-S45 (1994).
Dworkin et al. (2003) “Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations” Archives of Neurology, 60:1524-1534.
Eckhardt et al., “Gabapentin enhances the analgesic effect of morphine in healthy volunteers,” Anesth. Analges. 91:185-191 (2000).
Eldon et al., “Lack of effect of gabapentin on the pharmacokinetics of a norethindrone acetate/ethinyl estradiol-containing oral contraceptive,” Neurology 43:A307 (1993)

Affiliated with

Also associated with

Rating

Gastric retained gabapentin dosage form does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gastric retained gabapentin dosage form, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastric retained gabapentin dosage form will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4248972